Abstract
Immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pediatric patients with malignant disease may be affected by tumor therapy. Here, we report the case of a child with rhabdomyosarcoma and recurrent SARS-CoV-2 infection. Immunologic responses, analyzed by T-cell activity and anti-viral IgG levels, were impaired and not durable as a result of intensive radiochemotherapy.
All Keywords
【초록키워드】 SARS-CoV-2, coronavirus, therapy, SARS-COV-2 infection, Infection, Anti-viral, response, T-cell, Intensive, acute respiratory syndrome, Pediatric patient, IgG levels, malignant disease, Immunologic, responses, analyzed, affected, 【제목키워드】 SARS-CoV-2, response, Recurrent, while, Immunologic, Impaired,
【초록키워드】 SARS-CoV-2, coronavirus, therapy, SARS-COV-2 infection, Infection, Anti-viral, response, T-cell, Intensive, acute respiratory syndrome, Pediatric patient, IgG levels, malignant disease, Immunologic, responses, analyzed, affected, 【제목키워드】 SARS-CoV-2, response, Recurrent, while, Immunologic, Impaired,
{{{ 추상적인 }}}
악성 질환이 있는 소아 환자의 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2) 감염에 대한 면역 반응은 종양 요법의 영향을 받을 수 있습니다. 여기에서는 횡문근육종이 있는 아동과 재발성 SARS-CoV-2 감염 사례를 보고합니다. T-세포 활성과 항바이러스성 IgG 수치로 분석한 면역학적 반응은 집중적인 방사선화학요법의 결과 손상되었고 내구성이 없었습니다.